AVXL vs. RARE, VKTX, KNSA, CGON, MOR, GMTX, APLS, IMVT, HCM, and OGN
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Ultragenyx Pharmaceutical (RARE), Viking Therapeutics (VKTX), Kiniksa Pharmaceuticals International (KNSA), CG Oncology (CGON), MorphoSys (MOR), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), HUTCHMED (HCM), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs. Its Competitors
Ultragenyx Pharmaceutical (NASDAQ:RARE) and Anavex Life Sciences (NASDAQ:AVXL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Anavex Life Sciences has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Ultragenyx Pharmaceutical presently has a consensus target price of $81.50, suggesting a potential upside of 161.13%. Anavex Life Sciences has a consensus target price of $44.00, suggesting a potential upside of 341.77%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
In the previous week, Anavex Life Sciences had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 16 mentions for Anavex Life Sciences and 8 mentions for Ultragenyx Pharmaceutical. Anavex Life Sciences' average media sentiment score of 0.40 beat Ultragenyx Pharmaceutical's score of 0.31 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
Anavex Life Sciences has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. Anavex Life Sciences' return on equity of -45.67% beat Ultragenyx Pharmaceutical's return on equity.
Summary
Anavex Life Sciences beats Ultragenyx Pharmaceutical on 9 of the 15 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 10/6/2025 by MarketBeat.com Staff
